BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give BeOne Medicines a consensus "Moderate Buy" rating from 13 analysts (10 buys, 2 holds, 1 sell) with an average 1‑year price target of $389.73.
• In the latest quarter the company missed EPS ($0.58 vs. $1.60 estimate) while beating revenue ($1.50B vs. $1.45B); the stock trades around $293.86 with a market cap of $32.24B and a P/E of 116.61.
• Insiders sold 2,333 shares in the last three months (including 332 shares by an SVP) and own 6.62% of the stock, while institutional investors hold 48.55%.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) has received a consensus rating of "Moderate Buy" from the thirteen analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $389.7273.

Several equities research analysts recently issued reports on ONC shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of BeOne Medicines in a research note on Monday, April 20th. Morgan Stanley reiterated an "overweight" rating and issued a $405.00 price target on shares of BeOne Medicines in a research note on Thursday, January 8th. Wall Street Zen cut BeOne Medicines from a "strong-buy" rating to a "buy" rating in a research note on Saturday, February 28th. Guggenheim boosted their price target on BeOne Medicines from $400.00 to $410.00 and gave the company a "buy" rating in a research note on Friday, February 27th. Finally, Jefferies Financial Group cut BeOne Medicines from a "buy" rating to a "hold" rating and cut their price target for the company from $420.00 to $290.00 in a research note on Monday, March 16th.

BeOne Medicines Stock Performance

Shares of ONC stock opened at $293.86 on Monday. The company has a current ratio of 3.41, a quick ratio of 3.08 and a debt-to-equity ratio of 0.22. The stock has a market cap of $32.24 billion, a P/E ratio of 116.61 and a beta of 0.50. The stock has a 50 day simple moving average of $304.88 and a 200 day simple moving average of $322.16. BeOne Medicines has a 1 year low of $218.31 and a 1 year high of $385.22.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($1.02). The company had revenue of $1.50 billion during the quarter, compared to the consensus estimate of $1.45 billion. BeOne Medicines had a net margin of 5.37% and a return on equity of 10.70%. On average, research analysts predict that BeOne Medicines will post 5.44 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other BeOne Medicines news, SVP Chan Henry Lee sold 332 shares of the company's stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $311.59, for a total transaction of $103,447.88. Following the completion of the sale, the senior vice president directly owned 318,370 shares in the company, valued at $99,200,908.30. This represents a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 2,333 shares of company stock worth $785,951 in the last three months. 6.62% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BeOne Medicines

Hedge funds and other institutional investors have recently bought and sold shares of the company. Fiera Capital Corp grew its position in BeOne Medicines by 20.1% during the 3rd quarter. Fiera Capital Corp now owns 25,117 shares of the company's stock worth $8,557,000 after acquiring an additional 4,205 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in BeOne Medicines by 1,019.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 42,816 shares of the company's stock worth $14,587,000 after acquiring an additional 38,992 shares during the last quarter. Clear Harbor Asset Management LLC bought a new stake in BeOne Medicines during the 3rd quarter worth $548,000. AIA Group Ltd grew its position in BeOne Medicines by 31.4% during the 3rd quarter. AIA Group Ltd now owns 32,303 shares of the company's stock worth $11,006,000 after acquiring an additional 7,716 shares during the last quarter. Finally, Slow Capital Inc. grew its position in BeOne Medicines by 51.5% during the 4th quarter. Slow Capital Inc. now owns 27,301 shares of the company's stock worth $8,294,000 after acquiring an additional 9,280 shares during the last quarter. Institutional investors own 48.55% of the company's stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.